Uveitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Uveitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Uveitis disease pipeline drugs development. This report studies the dynamics of the Uveitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Uveitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development. Uveitis refers to the inflammation of uvea which is the middle layer of the eyeball. This may occur from either infectious or non-infectious cause. Retina is the sensitive part of the eye, uvea supplies blood to retina. Usually, uveitis is not serious, but if it is untreated may lead to vision loss. Symptoms may include, redness of eye, pain, dark floating spots on vision, blurred vision and others. There are many possible causes for uveitis including, entry of toxic substances and autoimmune diseases also lead to uveitis. Diagnosis is through the normal eye examination and treatment is given for the underlying diseases if any. Usually, corticosteroid eye drops are suggested to fight against the inflammation. Further, if not work oral or parenteral drugs may be given.